1- Vassilopoulou-Sellin R, Schultz PN. 2001 Adrenocortical carcinoma. Cancer. 92: 1113-21.

2- Latronico AC, Chrousos GP. 1997 Extensive Personal Experience: Adrenocortical tumors. J Clin Endocrinol Metab. 82: 1317- 1324.

3- Ross NS, Aron DC. 1990 Hormonal evaluation of the patient with an incidentally discovered adrenal mass. The New England Journal of Medicine. 323: 1401-1405.

4- Third National Cancer Survey: Incidence Data National Cancer Institute Monograph 41. March 1975. DHEW Publication No. (NIH) 75-787; US Department of Health. Education and Welfare: Public Health Service, National Institute of Health, National Cancer Institute, Bethesda, Maryland.

5- Young JL Jr, Miller RW. 1975 Incidence of malignant tumors in U.S. children. J Pediatrics. 86: 254-258.

6- Sandrini R, Ribeiro RC, DeLacerda. 1997 Childhood adrenocortical tumors. J Clin Endocrinol Metab 81: 2027-2031.

7- Mendonca BB, Lucon AM, Menezes CAV et al. 1995 Clinical, hormonal and pathological findings in a comparative study of adrenal cortical neoplasms in childhood and adulthood. J Urol 154: 2004-2009.

8- Wajchenberg BL, Albergaria Pereira MA, Mendonca BB, Latronico AC, Campos Carneiro P, Ferreira Alves VA, Zerbini MC, Liberman B, Carlos Gomes G, Kirschner MA. 2000 Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 88: 711-736.

9- Sullivan M, Boileau M, Hodges CV. 1978 Adrenal cortical carcinoma. The Journal of Urology. 120: 660-665.

10- Bertagna C, Orth David. 1981 Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). The American Journal of Medicine. 71: 855-875.

11- Nader S, Hickey RC, Sellin RV, Samaan NA. 1983 Adrenal cortical carcinoma. A study of 77 cases. Cancer. 52: 707-711.

12- Henley DJ, van Heerden JA, Grant CS, Carney A, Carpenter PC. 1983 Adrenal cortical carcinoma- A continuing chalenge. Surgery. 94: 926-931.

13- Chudler RM, Kay R. Adrenocortical carcinoma in children. 1989 Urologic Clinics of North America, vol.16, 3: 469-479.

14- Barzilay JI, Pazianos AG. 1989 Adrenocortical Carcinoma. Urologic Clinics of North America. vol 16, No 3:457-468.

15- Ribeiro RC, Sandrini Neto RS, Schell MJ, Lacerda L, Sampaio GA. 1990 Adrenocortical carcinoma in children: a study of 40 cases. J Clin Oncol. 8: 67-74.

16- Pommier RF, Brennan MF. 1992 An eleven-year experience with adrenocortical carcinoma. Surgery. 112: 963-971.

17- Flack MR, Chrousos GP. 1993 Neoplasms of adrenal cortex. Cancer Medicine, third edition, 1: 1147-1153.

18- Eguchi T, Tokuyama A, Tanaka Y, Takahashi Y, Kawahara G, Aiba M, Inishi Y, Minowa H. 2001 Hypoglicemia associated with the production of insuli-like growth factor in adrenocortical carcinoma. Intern Med. 40: 759-63.

19- Crapo, L. Cushing's syndrome: 1979 A review of diagnostic test. Metabolism. 28: 955-977.

20- Jones GS, Shan KJ, Mann JR. 1985 Adreno-cortical carcinoma in infancy and childhood: a radiological report of ten cases. Clin Radiol. 36: 257-262.

21- Shapiro B, Fig LM, Gross MD, Khafagi F. 1990 Contributions of Nuclear Endocrinology to the diagnosis of adrenal tumors. Recents Results in Cancer Research. 118: 113-138.

22- Eghari M, McLoughlin MJ, Rose IE, et al. 1980 The role of computed tomography in assessment of tumoral pathology of the adrenal glands. J Comput Assist Tomogr. 4: 71-77.

23- Glazer Gm, Woolsey EJ, Borello J, et al. 1986 Adrenal tissue characterization using MRI imaging. Radiology. 158: 73-79.

24- Saeger. 1990 Tumours of the adrenal gland. Recent Results in Cancer Research. 118: 79-96.

25- Kouriefs C, Mokbel K, Choy C. 2001 Is MRI more accurate than CT in estimating the real size of adrenal tumours?. Eur J Surg Oncol 27: 487-490.

26- Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsh CM. 2001 Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie 55: 367-377.

27- Becherer A, Vierhapper H, Potzi C et al. 2001 FDG-PET in adrenocortical carcinomas. Cancer Biother Radiopharm. 16: 289-95.

28- Hogan TF, Gilchrist KW, Westring DW, et al. 1980 A clinical and pathological study of adrenocortical carcinoma: therapeutics implications. Cancer. 45: 2880-2883.

29- Weiss LM. 1984 Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 8: 163-169.

30- Bowlby LS, DeBault L, Abraham SR. 1986 Flow cytometric analysis of adrenal cortical tumor DNA. Cancer. 58: 1499-1505.

31- Taylor S, Roederer M, Murphy R. 1987 Flow cytometric DNA analysis of adrenocortical tumors in children. Cancer. 59: 2059-2063.

32- Wachenfeld C, Beuschlein F, Zwermann O, Mora P, Fassnacht M, Allolio B, Reincke M. 2001 Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur J Endocrinol 145: 335-341.

33- Koch C, Pacak K, Chrousos GP 2002 The molecular pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors. J Clin Endocrinol. Metab, in press

34- Luton JP, Cerdas S, Billaud L, et al. 1990 Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. N Engl J Med. 322: 1195-1201.

35- Schteingart DE, Motazedi A, Noonan RA, Thompson NW. 1982 Treatment of adrenal carcinomas. Arch Surg. 117: 1142-1146.

36- Dickstein G, Shechner C, Arad E, Best LA, Nativ O. 1998 Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab. 83: 3100-3103.

37- Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogliotti L, Angeli A . 2000 Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab. 85: 2234-2238.

38- Flack MR, Pyle RG, Mullen NM, Lorenzo B, Wu YW, Knazek. Nisula BC, Reidenberg MM. 1993 Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol and Metab. 76: 1019-1024.

39- Haq MM, Legha SS, Samaan NA, Bodey GP, et al. 1980 Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep. 64: 909-913.

40- Hesketh PJ, McCaffrey RP, Finkel HE et al. 1987 Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep. 71: 222-224.

41- Johnson DH, Greco FA. 1986 Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer. 58: 2198-2202.

42- Schlumberger M, Ostronoff M, Bellaiche M et al. 1988 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. Cancer. 61: 1492-1494.

43- van Slooten H, van Oosterom AT. 1983 CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical. Cancer Treat Rep. 67: 377-379.

44- Ahlman H, Khorram-Manesh A, Jansson S, Wangberg B, Nilsson O, Jacobsson CE, Lindstedt S. 2001 Cytotoxic treatment of adrenocortical carcinoma. Word J Surg, 25: 927-933.

45- Williamson SK, Lew D, Miller GL, Balcerzak SP, Baker LH, Crwford ED. 2000 Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic carcinoma: a Southwest Oncology Group Study. Cancer. 88: 1159-1165.